What Clinicians Need to Know About Oral Antivirals for COVID-19: An Expert Q&A
In this Q&A, Erica Johnson, MD, provides insight into the new oral antiviral medications that may soon be approved for the treatment of COVID-19.
Diagnosis & Disease Information
Are Adult Men at Increased Risk for Myocarditis After COVID-19 mRNA Vaccination?
Using the Mayo Clinic’s COVID-19 Vaccine Registry, researchers were able to measure the incidence of myocarditis after patients received COVID-19 mRNA vaccination.
Moderna to Test COVID-19 Booster Candidates Against Omicron Variant
A new booster candidate specific for Omicron is also being planned.
ACS Risk Biomarkers Significantly Increase After mRNA COVID-19 Vaccine
Increases in PULS Cardiac Test scores after mRNA vaccinations suggest a significantly higher risk of developing acute coronary syndrome, according to findings presented at AHA 2021.
Breakthrough COVID-19 May Be More Common in Patients With Lymphoid Malignancies
About 81% of patients had lymphoproliferative malignancies.
Preparing for COVID-19 Vaccinations in Children
To answer the many questions regarding the roll out, risk and benefits, and timing of COVID-19 vaccine administration in children aged 5 to 11 years, The Clinical Advisor interviewed Mary Koslap-Petraco, DNP, PPCNP-BC, CPNP, FAANP, a pediatric nurse practitioner and owner of Pediatric Nurse Practitioner House Calls.
FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine for Younger Kids
For children 5 to 11 years of age, the vaccine is administered as a 2-dose series (10mcg each dose), separated by 3 weeks.
Nasal Spray With Iota-Carrageenan Decreases Risk for COVID-19 in Exposed Healthcare Workers
Investigators conducted a study to determine whether iota-carrageenan nasal spray decreases the risk for SARS-CoV-2 infection among health care workers managing patients with COVID-19.
Vaccinated Individuals Can Pass COVID-19 Infection to Household Contacts
The UK study aimed to investigate SARS-CoV-2 transmission and viral load in vaccinated and unvaccinated people with mild Delta variant infection.
Trial Results Show Efficacy High With Pfizer-BioNTech COVID-19 Booster Dose
The trial included more than 10,000 individuals who previously completed the primary 2-dose series of the Pfizer-BioNTech vaccine.
- Loading...
Loading...
Next post in News
Loading... 
Loading...